EARNINGS UPDATE
Biotechnology
November 14, 2013

Simos Simeonidis, Ph.D.
simos.simeonidis@cowen.com 646.562.1386
Yatin Suneja
yatin.suneja@cowen.com 646.562.1388
Raymond Chang, M.D.
raymond.chang@cowen.com 646.562.1337

Recommendation

Rating:	Outperform
Price Target (in $):	NA
Dividend:	NA
Enterprise Value (MM):	$59.0

Earnings Per Share

	2012A	2013E	2014E
Q1	--	--	*$(0.36)*
Q2	--	--	*$(0.38)*
Q3	--	*$(4.81)A*	*$(0.37)*
Prev:	--	*$(0.41)*	*$(0.38)*
Q4	--	*$(0.29)*	*$(0.38)*
Prev:	--	*$(0.30)*	*$(0.37)*
FY	*$(13.06)*	*$(2.76)*	*$(1.49)*
Prev:	--	*$(1.78)*	--

Stock Statistics as of 11/13/2013 (in $)

Price:	$5.16
52W Range:	$9.19-$4.30
Shares Out (MM):	22.2
Market Cap (MM):	$115.0
Net Debt (MM):	$2.8
Net Cash Per Share:	$2.52

Fundamentals

Revenue (MM) ('12A)	2.7
Revenue (MM) ('13E)	1.0
Revenue (MM) ('14E)	0.0



FATE THERAPEUTICS, INC. (NASDAQ:FATE)

ProHema Phase II to resume 1H14, data mid-2015; Wnt7a in clinic 2015

FATE reported 3Q13 results last night & held its first earnings call as a public company, after its 10/1/13 IPO. The Phase II ProHema-03 trial is expected to resume enrollment in 1H14, with full data mid-2015. Two Wnt7a candidates have been selected for further study, and one will advance to Phase I in 2015.

Phase II ProHema-03 trial expected to resume in 1H14, data mid-2015

Fate reported that it is producing the ProHema NRM (nutrient rich media) formulation and expects availability for manufacturing of clinical product in 1Q14. Fate plans to resume enrollment in the Phase II ProHema-03 trial in patients with hematologic malignancies in 1H14, with full data expected mid-2015. Seven out of 8 clinical sites have already approved protocol amendments for use of the NRM formulation, with the remaining site expected in 4Q13. Two to 4 more trial sites may be added, with a goal of 10 to 12 total participating centers. Safety reviews in the trial are planned after the first 6 and 12 patients have been treated with ProHema. An update on the trial, including time to engraftment data, is expected after these reviews.

Wnt7a Phase I studies planned for 2015

Fate reported that two Wnt7a analogs have been selected for IND-enabling activities, including manufacturing cell-line development and further characterization with *in vivo* dosing studies, PK, and toxicology assessments. Fate plans to advance one candidate into Phase I development in 2015, with initial focus on safety and bioactivity.

3Q13 numbers: cash "through late 2015"

Fate spent $5.4M ($3.4M in R&D, $2M in SG&A) in 3Q13 vs. $4.2M ($3.3M in R&D, $0.9M in SG&A) spent in 3Q12, ending 3Q13 with $59.1M in cash, which, according to the company, is sufficient to fund operations through late 2015. In 2Q13 and 3Q13, the company raised $23.7M through the issuance of convertible notes, which were converted into common stock at the IPO. In October 2013, Fate raised $46M in gross proceeds from its IPO by issuing 7.7M shares at $6/share. Net proceeds from these financing activities were $62.4M.

Please see addendum of this report for important disclosures.

IP broadened with two new patents. Fate reported that in October 2013, the US Patent and Trademark Office issued 2 patents related to ex vivo pharmacologic modulation of HSCs in patients undergoing HSCT, which expire in 2027: 1) US patent 8,551,782 ("Methods for Promoting HSC Engraftment"), and 2) US patent 8,563,310 ("Methods for Promoting Hematopoietic Reconstitution"). These patents are part of an IP portfolio licensed from Children's Medical Center Corporation and The General Hospital Corporation.

What's next for FATE? 1) Resumption of enrollment in Phase II ProHema-03 trial, 1H14; **2)** Initiation of Phase Ib trial of ProHema in pediatric patients, mid-2014; **3)** Interim safety check in ProHema-03, 2H14; **4)** Initiation of Phase I trial of ProHema in lysosomal storage disorders, 2H14; **5)** IND submission for Wnt7a, YE14; **6)** Full data from Phase II ProHema-03 trial, mid-2015; and **7)** Initiation of Wnt7a Phase I program, 2015.

Our thesis on FATE. Our thesis is based on the company's core technology and expertise in the pharmacologic modulation of adult stem cells for the development of therapeutics for treatment of orphan diseases. If successful in its Phase II and Phase III development, we estimate that ProHema can gain significant share in the umbilical cord blood-derived HSCT market, along with shares in the bone marrow- and peripheral blood-derived markets as well. Using conservative market penetration assumptions for ProHema (*16% of the overall allogeneic HSCT market*), we project that it can be a $360M US/EU product in 2025, with peak US/EU sales of ~$515M in 2030. These revenue numbers do not account for the upside that exists, should ProHema and follow-on products manage to demonstrate utility in rare genetic disorders for which transplantation is not currently used as the standard of care, but is being used investigationally and is starting to emerge as a potential treatment option.

Fate is also using its understanding of stem cell biology to develop *in vivo* modulators of muscle satellite stem cells (SSCs). Specifically, preclinical experiments have shown that administration of a recombinant Wnt7a protein can lead to expansion of SSCs and improve the regenerative capacity of muscle. These results have obvious implications for and potential in the treatment of muscular dystrophies. Fate has selected two Wnt7a analog drug candidates for IND-enabling activities and plans to initiate Phase I clinical development in DMD in 2015. With the obvious caveat that this work is still in its very early stages, a quick look at the valuations of companies working in DMD highlights to us the commercial potential and investor interest in the space. We believe that the combination of the ProHema opportunity with the potential upside from the Wnt7a program make FATE an attractive early stage biotech play, and we reiterate our Outperform rating.

Investment Thesis

Our thesis on FATE is based on the company's core technology and expertise in the pharmacologic modulation of adult stem cells for the development of therapeutics for treatment of orphan diseases.

ProHema: better outcomes for patients undergoing stem cell transplantation. Fate's deep expertise in and understanding of stem cell biology has culminated in the development of ProHema, a cell therapy product for use in patients undergoing hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. The concept behind the development of ProHema is that small molecule modulators can potentially be added to unmodulated hematopoietic stem cells (HSCs) before a HSCT, thereby improving the safety profile and the outcome of the procedure. By pharmacologically optimizing HSCs *ex vivo*, in preclinical experiments, treatment with ProHema resulted in doubling in the "homing" of transplanted cells to the marrow and quadrupling of their engraftment. Results from the first Phase I clinical trial of ProHema in 12 patients were equally promising, with improvements in median time to engraftment, % engrafted, and overall outcomes. The company is now planning to resume enrollment in the Phase II ProHema-03 trial in adult patients undergoing HSCT for hematologic malignancies in 1H14. In addition, the company is planning on conducting two pediatric trials in 2014: the first one in patients undergoing HSCT for hematologic malignancies, expected to start in mid-2014, and the second one in patients undergoing HSCT to treat lysosomal storage disorders (LSDs), expected to start in 2H14.

The tangible commercial opportunity for ProHema…There are approximately 8,000 allogeneic HSCTs performed in the US each year, and another 15,000 in the EU. Approximately 15-20% of these procedures use umbilical cord blood as their source, which is the setting Fate has used for its trials thus far and will be using for its Phase II trial. If successful in its Phase II and Phase III development, we estimate that ProHema can gain significant share in the umbilical cord blood-derived HSCT market, along with share in the bone marrow- and peripheral blood-derived markets as well. Using conservative market penetration assumptions for ProHema (*16% of the overall allogeneic HSCT market*), we project that it can be a $360M US/EU product in 2025, with peak US/EU sales of ~$515M in 2030.

…and the potential upside: These revenue numbers do not account for the upside that exists, should ProHema and follow-on products manage to demonstrate utility in rare genetic disorders for which transplantation is not currently used as the standard of care, but is being used investigationally and is starting to emerge as a potential treatment option. In addition, we have performed a scenario analysis, evaluating a number of alternative launch trajectories which result in different peak market penetrations, translating into significant revenue projections for ProHema. For simplicity, we have only looked at the allogeneic HSCT market in its steady state today, i.e., we have not increased the use of HSCTs significantly. Furthermore, we have kept the number of umbilical cord blood transplants as a proportion of the overall HSCT market steady, and have not increased the number of UCB-derived procedures, even though a number of sources indicate that the UCB portion of the market may be growing. Despite this conservative approach, it is clear that, should ProHema succeed in its clinical

development program, it could become a very successful commercial product, even by achieving modest market penetration, and without counting on significant market or umbilical cord blood segment growth.

Our consultants are positive on ProHema for hematologic malignancies: In order to get a better understanding of the ProHema clinical development program and its clinical and commercial potential, we consulted with five hematologist/oncologists specializing in HSCT at major, leading transplantation centers across the US. This group included specialists in both adult and pediatric stem cell transplantation. All of our consultants had significant clinical practices including allogeneic HSCT and the use of umbilical cord blood as a cell source. Additionally, each of our experts was familiar with ProHema, and some were participants in ProHema clinical trials. Our consultants view ProHema as easy to use (*"rather straightforward," "a very simple type of technique," "practical, not at all problematic"*). With regard to the ProHema data, all of our experts noted the early nature of the results, but did feel that the data were "*interesting*" and *"promising."* In particular, they appeared to be intrigued by the underlying strategy of ProHema modulation for homing enhancement, and differentiated this from other approaches focused on *ex vivo* expansion of cord blood cells, which were viewed generally as "*laborious,*" "*expensive,*" and "*time-consuming.*" While all our consultants did view the preliminary ProHema data to have potential, the group was somewhat split on the strength of the clinical results thus far, in particular regarding the reduction in time to neutrophil engraftment reported in the Phase I trial (compared to historical control). On the one hand, there were a couple physicians who viewed the reduction in engraftment time of 3-4 days as *"clinically meaningful,"* given that the longer amount of time a patient is neutropenic leads to an increased risk of transplant-related morbidity. They felt that this improvement would reduce length of stay in the hospital, leading to relative risk reduction for the patient, as well as potential cost savings (a meaningful economic benefit). On the other hand, there were two physicians in our group who questioned the impact, stating *"I'm not sure if 3 days is overall meaningful"* and asking, *"is it meaningful in terms of death and infections?"* Overall, our consultants felt that there is a *"reasonable"* chance of a successful ProHema clinical trial program and ultimately approval, if meaningful improvements can be demonstrated in hematopoietic recovery. One of our experts remarked that knowing Fate is working with the FDA on design of a trial which will support an approval pathway provides further confidence. In terms of potential uptake of ProHema, if approved, our physicians were aligned in expressing a reasonable chance of adoption as well.

ProHema for Rare Genetic Disorders. In addition to the use of ProHema in patients undergoing HSCT for hematologic malignancies, Fate is also pursuing the potential use of pharmacologically modulated HSCs for allogeneic HSCT treatment of rare genetic disorders. The company is planning to evaluate ProHema in an initial clinical trial of pediatric patients with demyelinating lysosomal storage disorders (LSDs). Also, an active research program is being undertaken to develop a second generation HSC therapeutic, which will be specifically designed to enhance the homing of HSCs to the central nervous system (CNS), in order to enhance delivery of essential enzymes to patients with deficiencies.

LSD consultants intrigued by ProHema approach: Our three LSD consultants had positive views on the theoretical potential for pharmacologic modulation in the setting of allogeneic HSCT for LSDs. One of our experts called ProHema *"a very good idea"* and felt that it may be relevant in LSD treatment, as *"it does work in the setting of regular homing to bone marrow…and the niche in CNS resembles the niche in bone marrow."* Our second expert agreed on the rationale of ProHema in this setting, and felt that it was a *"step in the right direction, as one of the goals of transplant is homing into the brain"* for LSDs. At the same time, while this expert noted the early ProHema data to be promising, he was also clear that *"the acceleration of engraftment was not a home run,"* referring to the Phase I trial result. He desired to see an improvement of 7 to 10 days. Our third expert agreed that the improvement in hematopoietic recovery thus far of around 3-4 days may not in and of itself be game-changing, but he was more excited about seeing a potential increase in CNS homing, which "*may open transplant up to diseases which we are not currently transplanting"* and *"could be a big deal."*

Wnt7a analog work is very early, but we believe it has the most upside potential. Fate is also using its understanding of stem cell biology to develop *in vivo* modulators of muscle satellite stem cells (SSCs). Specifically, preclinical experiments have shown that administration of a recombinant Wnt7a protein can lead to expansion of SSCs and improve the regenerative capacity of muscle. These results have obvious implications for and potential in the treatment of muscular dystrophies. Fate has selected two Wnt7a analog drug candidates for IND-enabling activities and plans to initiate Phase I clinical development in DMD in 2015. With the obvious caveat that this work is still in its very early stages, a quick look at the valuations of companies working in DMD highlights to us the commercial potential and investor interest in the space.

DMD consultant excited about Wnt7a program: Our consultant, a neurologist and neuroscientist specializing in genetic muscle disorders at a major academic medical institution, was *"optimistic"* about Wnt7a-based therapy and felt that *"it is possible it will work"* in DMD. Our expert indicated that Wnt signaling has an important role in muscle stem cell proliferation and considered the rationale of this therapy to be solid, since *"a lot of the problem in DMD is lack of muscle regeneration."* Our expert pointed out the very early nature of the preclinical data which have been produced to date, and emphasized the long path from this stage to advanced clinical development and potential approval. She described the data as *"encouraging"* and remarked that the results to date *"very convincingly"* demonstrate increase in muscle mass, force, and histopathology as a result of Wnt7a administration in the mouse model.

Company Description

Fate Therapeutics is a biotechnology company developing pharmacologic modulators of adult stem cells for the treatment of difficult to treat, orphan diseases. Fate's hematopoietic stem cell (HSC) modulation platform is focused on the *ex vivo* optimization of HSCs used in allogeneic stem cell transplantation (HSCT). Fate's lead program is ProHema, a HSC therapeutic produced by pharmacologic modulation of umbilical cord blood, which is currently in Phase II development for hematologic malignancies in adult patients. The company plans to investigate ProHema in the pediatric population for indications in hematologic malignancies (mid-2014) and rare, genetic lysosomal storage disorders (LSDs) (2H14). Fate is also developing an *in vivo* modulation strategy for muscle stem cells, known as satellite stem cells (SSC), using a Wnt7a therapeutic to improve muscle regeneration, with application in treatment of muscular dystrophies. This program is in preclinical development, with two candidates selected for IND-enabling activities, IND submission anticipated by YE14, and advancement of one Wnt7a candidate into Phase I expected in 2015. Fate was founded in 2007 and went public in October 2013. The company is headquartered in San Diego, CA and has 33 employees.

Fate: R&D Pipeline

Candidate name	Indication	P-C	I	II	III	FILING	MKT	Comments
HSC Modulation Platform								
ProHema	Adult hematologic malignancies			•				Resume enrollment in Phase II ProHema-03 trial, 1H14
ProHema	Pediatric hematologic malignancies	•						Initiate a Phase Ib trial in pediatric population, mid-14
ProHema	Lysosomal storage disorders	•						Initiate a Phase I trial in pediatric population, 2H14
2nd-generation HSC Therapeutic	Lysosomal storage disorders	•						-
SSC Modulation Platform								
Wnt7a Protein Analogs	Muscular dystrophies	•						Submit IND application YE14
Wnt7a Protein Analogs	Neuromuscular disorders	•						-
Total Drugs in Development		**5**	**0**	**1**	**0**	**0**	**0**	
San Diego, CA	**Investor Relations Contact: Paul Cox - 212.362.1200**							

Source: Cowen and Company

Fate: Expected Milestones

Milestones	Timing
ProHema	
Resume enrollment in the Phase II ProHema-03 trial with new media in adults	1H14
Initiate Phase Ib trial of ProHema in pediatric patients	mid-2014
Initiate Phase I trial of ProHema in lysosomal storage disorders (LSDs)	2H14
Interim safety check in ProHema-03 trial	***2H14***
Data from Phase II ProHema-03 trial of ProHema in adults	***mid-2015***
Data from Phase Ib trial of ProHema in pediatric patients	2015
Initiate Phase III trial of ProHema in adults/pediatric patients	2H15
Wnt7a	
Submit IND application for Wnt7a	YE14
Initiate Phase Ia dose exploration trial of Wnt7a in healthy volunteers	2015
Data from a Phase Ia dose exploration trial of Wnt7a in healthy volunteers	1H15
Initiate Phase Ib multi-dose trial of Wnt7a in DMD patients	2H15

Source: Cowen and Company

ProHema Hematology HSCT Revenue Model ($MM)

US ProHema Revenue Model	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
US population	319,455,250	322,266,457	325,102,401	327,963,303	330,849,380	333,760,854	336,697,950	339,660,892	342,649,907	345,665,227	348,707,081	351,775,703	354,871,329	357,994,197	361,144,546	364,322,618	367,528,657	370,762,909
Population growth	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*	*0.88%*
# of HSCT performed in the US	18,255	18,416	18,578	18,741	18,906	19,073	19,240	19,410	19,581	19,753	19,927	20,102	20,279	20,457	20,637	20,819	21,002	21,187
# of autologous HSCT	10,587	10,680	10,774	10,869	10,965	11,061	11,158	11,257	11,356	11,456	11,556	11,658	11,761	11,864	11,969	12,074	12,180	12,287
% of autologous HSCT	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*	*58%*
# of allogeneic HSCT	**7,668**	**7,736**	**7,804**	**7,872**	**7,942**	**8,012**	**8,082**	**8,153**	**8,225**	**8,297**	**8,370**	**8,444**	**8,518**	**8,593**	**8,669**	**8,745**	**8,822**	**8,900**
% of allogeneic HSCT	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*	*42%*
% of cord blood derived HSCT	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*
# of cord blood derived HSCT	1,150	1,160	1,171	1,181	1,191	1,202	1,212	1,223	1,234	1,245	1,256	1,267	1,278	1,289	1,300	1,312	1,323	1,335
% of cord blood derived HSCT performed with ProHema							*18%*	*29%*	*38%*	*45%*	*50%*	*50%*	*50%*	*50%*	*50%*	*50%*	*50%*	*50%*
# of cord blood derived HSCT performed with ProHema	-	-	-	-	-	-	**218**	**355**	**469**	**560**	**628**	**633**	**639**	**644**	**650**	**656**	**662**	**667**
% of bone marrow derived HSCT	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*
# of bone marrow derived HSCT	1,534	1,547	1,561	1,574	1,588	1,602	1,616	1,631	1,645	1,659	1,674	1,689	1,704	1,719	1,734	1,749	1,764	1,780
% of bone marrow derived HSCT performed with ProHema							*3%*	*6%*	*9%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*
# of bone marrow derived HSCT performed with ProHema	-	-	-	-	-	-	**48**	**98**	**148**	**232**	**234**	**236**	**239**	**241**	**243**	**245**	**247**	**249**
% of peripheral blood derived HSCT	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*
# of peripheral blood derived HSCT	4,984	5,028	5,072	5,117	5,162	5,208	5,253	5,300	5,346	5,393	5,441	5,489	5,537	5,586	5,635	5,684	5,734	5,785
% of peripheral blood derived HSCT performed with ProHema							*1%*	*3%*	*6%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*
# of peripheral blood derived HSCT performed with ProHema	-	-	-	-	-	-	**53**	**159**	**321**	**431**	**435**	**439**	**443**	**447**	**451**	**455**	**459**	**463**
# of allogeneic HSCT performed with ProHema	-	-	-	-	-	-	**319**	**611**	**938**	**1,224**	**1,297**	**1,309**	**1,320**	**1,332**	**1,344**	**1,356**	**1,367**	**1,379**
% penetration in allogeneic HSCT							*4%*	*8%*	*11%*	*15%*	*16%*	*16%*	*16%*	*16%*	*16%*	*16%*	*16%*	*16%*
Price per procedure		$75,000	$76,500	$78,030	$79,591	$81,182	$82,806	$87,774	$93,041	$98,623	$104,541	$110,813	$118,570	$126,870	$135,751	$145,253	$155,421	$166,301
% price increase		*2%*	*2%*	*2%*	*2%*	*2%*	*6%*	*6%*	*6%*	*6%*	*6%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*
Total US Sales ($MM)	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$26**	**$54**	**$87**	**$121**	**$136**	**$145**	**$157**	**$169**	**$182**	**$197**	**$213**	**$229**

EU ProHema Revenue Model	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EU population	504,393,906	504,898,300	505,403,198	505,908,601	506,414,510	506,920,925	507,427,845	507,935,273	508,443,209	508,951,652	509,460,603	509,970,064	510,480,034	510,990,514	511,501,505	512,013,006	512,525,019	513,037,544
Population growth	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*	*0.10%*
# of HSCT performed in the EU	35,731	35,767	35,803	35,839	35,874	35,910	35,946	35,982	36,018	36,054	36,090	36,126	36,162	36,199	36,235	36,271	36,307	36,344
% of autologous HSCT	21,153	21,174	21,196	21,217	21,238	21,259	21,280	21,302	21,323	21,344	21,366	21,387	21,408	21,430	21,451	21,473	21,494	21,516
# of autologous HSCT	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*	*59%*
# of allogeneic HSCT	**14,578**	**14,593**	**14,607**	**14,622**	**14,637**	**14,651**	**14,666**	**14,680**	**14,695**	**14,710**	**14,725**	**14,739**	**14,754**	**14,769**	**14,784**	**14,798**	**14,813**	**14,828**
% of allogeneic HSCT	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*	*41%*
% of cord blood HSCT	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*	*15%*
# of cord blood HSCT	2,187	2,189	2,191	2,193	2,195	2,198	2,200	2,202	2,204	2,206	2,209	2,211	2,213	2,215	2,218	2,220	2,222	2,224
% of cord blood HSCT performed with ProHema								*18%*	*29%*	*38%*	*45%*	*50%*	*50%*	*50%*	*50%*	*50%*	*50%*	*50%*
# of cord blood HSCT performed with ProHema	-	-	-	-	-	-	-	**396**	**639**	**838**	**994**	**1,105**	**1,107**	**1,108**	**1,109**	**1,110**	**1,111**	**1,112**
% of bone marrow derived HSCT	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*
# of bone marrow derived HSCT	2,916	2,919	2,921	2,924	2,927	2,930	2,933	2,936	2,939	2,942	2,945	2,948	2,951	2,954	2,957	2,960	2,963	2,966
% of bone marrow derived HSCT performed with ProHema								*3%*	*6%*	*9%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*	*14%*
# of bone marrow derived HSCT performed with ProHema	-	-	-	-	-	-	-	**88**	**176**	**265**	**412**	**413**	**413**	**414**	**414**	**414**	**415**	**415**
% of peripheral blood derived HSCT	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*	*65%*
# of peripheral blood derived HSCT	9,476	9,485	9,495	9,504	9,514	9,523	9,533	9,542	9,552	9,561	9,571	9,581	9,590	9,600	9,609	9,619	9,629	9,638
% of peripheral blood derived HSCT performed with ProHema								*1%*	*3%*	*6%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*	*8%*
# of peripheral blood derived HSCT performed with ProHema	-	-	-	-	-	-	-	**95**	**287**	**574**	**766**	**766**	**767**	**768**	**769**	**770**	**770**	**771**
# of allogeneic HSCT performed with ProHema	-	-	-	-	-	-	-	**580**	**1,102**	**1,677**	**2,172**	**2,285**	**2,287**	**2,289**	**2,291**	**2,294**	**2,296**	**2,298**
% penetration in allogeneic HSCT								*4%*	*8%*	*11%*	*15%*	*16%*	*16%*	*16%*	*16%*	*16%*	*16%*	*16%*
Price per procedure		$56,250	$57,375	$58,523	$59,693	$60,887	$62,105	$65,831	$69,781	$73,968	$78,406	$83,110	$88,928	$95,153	$101,813	$108,940	$116,566	$124,726
% price increase		*2%*	*2%*	*2%*	*2%*	*2%*	*6%*	*6%*	*6%*	*6%*	*6%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*	*7%*
Total EU Sales ($MM)	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$38**	**$77**	**$124**	**$170**	**$190**	**$203**	**$218**	**$233**	**$250**	**$268**	**$287**

Total US/EU sales ($MM)	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$26**	**$92**	**$164**	**$245**	**$306**	**$335**	**$360**	**$387**	**$416**	**$447**	**$480**	**$516**
US Sales ($MM) - Cord blood derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$18**	**$31**	**$44**	**$55**	**$66**	**$70**	**$76**	**$82**	**$88**	**$95**	**$103**	**$111**
EU Sales ($MM) - Cord blood derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$26**	**$45**	**$62**	**$78**	**$92**	**$98**	**$105**	**$113**	**$121**	**$130**	**$139**
Total US/EU Sales ($MM) - Cord blood derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$18**	**$57**	**$88**	**$117**	**$144**	**$162**	**$174**	**$187**	**$201**	**$216**	**$232**	**$250**
US Sales ($MM) - Bone marrow derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$4**	**$9**	**$14**	**$23**	**$25**	**$26**	**$28**	**$31**	**$33**	**$36**	**$38**	**$41**
EU Sales ($MM) - Bone marrow derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$6**	**$12**	**$20**	**$32**	**$34**	**$37**	**$39**	**$42**	**$45**	**$48**	**$52**
Total US/EU Sales ($MM) - Bone marrow derived HSCTs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$4**	**$14**	**$26**	**$42**	**$57**	**$60**	**$65**	**$70**	**$75**	**$81**	**$87**	**$93**
US Sales ($MM) - Peripheral blood derived HSCT	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$4**	**$14**	**$30**	**$43**	**$46**	**$49**	**$53**	**$57**	**$61**	**$66**	**$71**	**$77**
EU Sales ($MM) - Peripheral blood derived HSCT	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$6**	**$20**	**$42**	**$60**	**$64**	**$68**	**$73**	**$78**	**$84**	**$90**	**$96**
Total US/EU Sales ($MM) - Peripheral blood derived HSCT	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$4**	**$20**	**$50**	**$85**	**$106**	**$112**	**$121**	**$130**	**$139**	**$150**	**$161**	**$173**

Source: Cowen and Company

ProHema in Hematology– NPV Analysis

($MM)	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
ProHema Sales																		
Total US Sales	-	-	-	-	-	-	26.4	53.7	87.2	120.7	135.6	145.0	156.6	169.0	182.4	196.9	212.5	229.4
Total EU Sales	-	-	-	-	-	-	-	38.2	76.9	124.0	170.3	189.9	203.4	217.8	233.3	249.9	267.6	286.7
Total US/EU sales	**-**	**-**	**-**	**-**	**-**	**-**	**26.4**	**91.8**	**164.1**	**244.7**	**305.9**	**334.9**	**359.9**	**386.8**	**415.7**	**446.8**	**480.2**	**516.1**
ProHema Revenues to FATE																		
Total US Sales ($MM)	-	-	-	-	-	-	26.4	53.7	87.2	120.7	135.6	145.0	156.6	169.0	182.4	196.9	212.5	229.4
Total EU royalties ($MM)	-	-	-	-	-	-	-	6.9	14.6	24.8	35.8	41.8	44.7	47.9	53.7	57.5	61.6	65.9
Total Revenue to FATE ($MM)	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**26.4**	**60.5**	**101.9**	**145.5**	**171.4**	**186.8**	**201.3**	**216.9**	**236.1**	**254.4**	**274.1**	**295.3**
Milestone payments received from partner			50			30.0	-	25.0	20.0	-	20.0	-	20.0	-	-	-	-	-
COGS	-	-	-	-	-	-	4.0	8.1	13.1	18.1	20.3	21.8	23.5	25.3	27.4	29.5	31.9	34.4
Less royalties paid to Institutions	-	-	-	-	-	-	1.3	3.0	5.1	7.3	8.6	9.3	10.1	10.8	11.8	12.7	13.7	14.8
R&D	-	12.2	13.0	13.3	13.3	13.3	-	-	-	-	-	-	-	-	-	-	-	-
SG&A		5.0	5.2	4.4	3.6	18.8	19.0	20.1	20.5	20.8	21.1	21.5	21.8	22.2	22.5	22.9	23.3	23.7
Tax adjusted EBIT	-	(17.2)	31.8	(17.7)	(16.9)	(2.1)	2.2	51.6	77.4	87.4	123.0	114.1	136.1	123.7	127.3	136.2	147.8	160.2
Tax rate		*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*5%*	*7%*	*12%*	*13%*	*15%*	*18%*	*22%*	*27%*	*28%*	*28%*	*28%*
ProHema free cash flow	**0.0**	**(17.2)**	**31.8**	**(17.7)**	**(16.9)**	**(2.1)**	**2.2**	**51.6**	**77.4**	**87.4**	**123.0**	**114.1**	**136.1**	**123.7**	**127.3**	**136.2**	**147.8**	**160.2**
% y/y growth							*-206%*	*2253%*	*50%*	*13%*	*41%*	*-7%*	*19%*	*-9%*	*3%*	*7%*	*8%*	*8%*
Discount Period	*0.13*	*1.13*	*2.13*	*3.13*	*4.13*	*5.13*	*6.13*	*7.13*	*8.13*	*9.13*	*10.13*	*11.13*	*12.13*	*13.13*	*14.13*	*15.13*	*16.13*	*17.13*
Discount Factor	*0.99*	*0.90*	*0.82*	*0.74*	*0.67*	*0.61*	*0.56*	*0.51*	*0.46*	*0.42*	*0.38*	*0.35*	*0.31*	*0.29*	*0.26*	*0.24*	*0.21*	*0.20*
PV of ProHema FCF	**0.0**	**(15.4)**	**25.9**	**(13.2)**	**(11.4)**	**(1.3)**	**1.2**	**26.2**	**35.7**	**36.6**	**46.8**	**39.5**	**42.8**	**35.4**	**33.1**	**32.2**	**31.8**	**31.3**

Discount Rate	10%
Perpetual Growth Rate	0%
Final year FCF	$160
Terminal Value	$1,602
Discount Factor	0.20
Present Value of Terminal Value	**$313**
Present Value of Cash Flows	**$377**
Present Value of Total Cash Flows	**$690**
Fully Diluted Shares Outstanding	22
NPV of ProHema in Hematology	**$30.96**
Probability of Success of Phase II trial	***50%***
Probability of Success of Phase III trial	***67%***
Overall Probability of Success	***33%***
NPV of ProHema in Hematology (probability-adjusted)	**$10.32**

Source: Cowen and Company

FATE: Sum-of-the-parts analysis

ProHema in Hematology	$10.32
Technology value	$2.24
Net Cash	$2.52
Sum-of-the-parts total value for FATE	**$15.09**

Current	
Price	$5.16
% upside	192%
Shares OS	22
Market Cap	**$115**
Cash	$59
Debt	$3
Net Cash	$56
EV	**$59**

Source: Cowen and Company

FATE: Quarterly P&L ($MM)

($MM)	2011A	2012A	1H13A	Q3:13A	Q4:13E	2013E	Q1:14E	Q2:14E	Q3:14E	Q4:14E	2014E	2015E
ProHema Revenues to FATE												
Total US Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total EU royalties	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total ProHema revenues to FATE	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Collaboration revenue	0.8	1.3	0.4	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0
Grant revenue	0.3	1.4	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Milestone/License fee	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.0
Total revenue	**1.2**	**2.7**	**0.8**	**0.2**	**0.0**	**1.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**50.0**
COGS	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
R&D	**9.9**	**12.0**	**5.6**	**3.4**	**3.8**	**12.8**	**5.4**	**5.7**	**5.8**	**5.7**	**22.6**	**26.5**
SG&A	**4.6**	**4.2**	**2.8**	**2.0**	**2.1**	**6.9**	**2.0**	**2.1**	**2.0**	**2.2**	**8.3**	**8.7**
Total operating expenses	**14.5**	**16.2**	**8.4**	**5.4**	**5.9**	**19.6**	**7.4**	**7.8**	**7.8**	**7.9**	**30.9**	**35.2**
Operating Income/Loss	**(13.3)**	**(13.6)**	**(7.6)**	**(5.1)**	**(5.9)**	**(18.7)**	**(7.4)**	**(7.8)**	**(7.8)**	**(7.9)**	**(30.9)**	**14.8**
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest expense	(0.1)	(0.5)	(0.2)	0.0	(0.1)	(0.3)	(0.1)	(0.1)	(0.1)	(0.1)	(0.4)	0.0
Other income (expense)	(0.0)	(0.2)	(1.3)	(0.9)	0.0	(2.2)	0.0	0.0	0.0	0.0	0.0	0.0
Pretax income	(13.4)	(14.2)	(9.1)	(6.1)	(6.0)	(21.2)	(7.5)	(7.9)	(7.9)	(8.0)	(31.3)	14.8
Income tax expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net loss attributable to common stock	**(13.4)**	**(14.2)**	**(9.1)**	**(6.1)**	**(6.0)**	**(21.2)**	**(7.5)**	**(7.9)**	**(7.9)**	**(8.0)**	**(31.3)**	**14.8**
EPS (basic)	**($16.16)**	**($13.06)**	**($7.41)**	**($4.81)**	**($0.29)**	**($2.76)**	**($0.36)**	**($0.38)**	**($0.37)**	**($0.38)**	**($1.49)**	**$0.44**
EPS (diluted)	**($16.16)**	**($13.06)**	**($7.41)**	**($4.81)**	**($0.29)**	**($2.76)**	**($0.36)**	**($0.38)**	**($0.37)**	**($0.38)**	**($1.49)**	**$0.42**
Basic shares	0.8	1.1	1.2	1.3	20.5	7.7	20.7	20.9	21.1	21.3	21.0	33.3
Diluted shares	0.8	1.1	1.2	1.3	22.3	8.3	22.5	22.7	23.0	23.2	22.9	35.2

Source: Cowen and Company

FATE: Annual P&L ($MM)

($MM)	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
ProHema Revenues to FATE																				
Total US Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.4	53.7	87.2	120.7	135.6	145.0	156.6	169.0	182.4	196.9	212.5	229.4
Total EU royalties	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	14.6	24.8	35.8	41.8	44.7	47.9	53.7	57.5	61.6	65.9
Total ProHema revenues to FATE	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**26.4**	**60.5**	**101.9**	**145.5**	**171.4**	**186.8**	**201.3**	**216.9**	**236.1**	**254.4**	**274.1**	**295.3**
Collaboration revenue	0.8	1.3	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Grant revenue	0.3	1.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Milestone/License fee	0.0	0.0	0.0	0.0	50.0	0.0	0.0	30.0	0.0	25.0	20.0	0.0	20.0	0.0	20.0	0.0	0.0	0.0	0.0	0.0
Total revenue	**1.2**	**2.7**	**1.0**	**0.0**	**50.0**	**0.0**	**0.0**	**30.0**	**26.4**	**85.5**	**121.9**	**145.5**	**191.4**	**186.8**	**221.3**	**216.9**	**236.1**	**254.4**	**274.1**	**295.3**
COGS	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**5.3**	**11.1**	**18.2**	**25.4**	**28.9**	**31.1**	**33.5**	**36.2**	**39.2**	**42.3**	**45.6**	**49.2**
R&D	**9.9**	**12.0**	**12.8**	**22.6**	**26.5**	**34.5**	**39.7**	**41.0**	**41.9**	**42.9**	**46.8**	**52.9**	**63.2**	**62.4**	**71.7**	**71.1**	**75.5**	**82.9**	**89.4**	**94.9**
SG&A	**4.6**	**4.2**	**6.9**	**8.3**	**8.7**	**8.9**	**9.1**	**25.2**	**25.5**	**26.9**	**27.3**	**27.8**	**28.3**	**28.8**	**29.2**	**29.8**	**30.3**	**30.8**	**31.3**	**31.9**
Total operating expenses	**14.5**	**16.2**	**19.6**	**30.9**	**35.2**	**43.4**	**48.8**	**66.2**	**72.8**	**80.9**	**92.3**	**106.1**	**120.4**	**122.3**	**134.5**	**137.0**	**144.9**	**156.0**	**166.3**	**176.0**
Operating Income/Loss	**(13.3)**	**(13.6)**	**(18.7)**	**(30.9)**	**14.8**	**(43.4)**	**(48.8)**	**(36.2)**	**(46.3)**	**4.7**	**29.6**	**39.4**	**71.0**	**64.5**	**86.8**	**79.9**	**91.1**	**98.4**	**107.8**	**119.4**
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest expense	(0.1)	(0.5)	(0.3)	(0.4)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)	(0.0)	(0.2)	(2.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pretax income	(13.4)	(14.2)	(21.2)	(31.3)	14.8	(43.4)	(48.8)	(36.2)	(46.3)	4.7	29.6	39.4	71.0	64.5	86.8	79.9	91.1	98.4	107.8	119.4
Income tax expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.1	4.7	9.2	9.7	15.6	17.6	24.6	27.6	30.2	33.4
Tax rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*5%*	*7%*	*12%*	*13%*	*15%*	*18%*	*22%*	*27%*	*28%*	*28%*	*28%*
Net loss attributable to common stock	**(13.4)**	**(14.2)**	**(21.2)**	**(31.3)**	**14.8**	**(43.4)**	**(48.8)**	**(36.2)**	**(46.3)**	**4.4**	**27.5**	**34.7**	**61.8**	**54.8**	**71.1**	**62.3**	**66.5**	**70.8**	**77.6**	**85.9**
EPS (basic)	**($16.16)**	**($13.06)**	**($2.76)**	**($1.49)**	**$0.44**	**($1.25)**	**($1.35)**	**($0.97)**	**($1.19)**	**$0.11**	**$0.65**	**$0.79**	**$1.36**	**$1.16**	**$1.44**	**$1.22**	**$1.25**	**$1.28**	**$1.35**	**$1.43**
EPS (diluted)	**($16.16)**	**($13.06)**	**($2.76)**	**($1.49)**	**$0.42**	**($1.25)**	**($1.35)**	**($0.97)**	**($1.19)**	**$0.10**	**$0.62**	**$0.75**	**$1.28**	**$1.09**	**$1.36**	**$1.15**	**$1.18**	**$1.21**	**$1.27**	**$1.35**
Basic shares	0.8	1.1	7.7	21.0	33.3	34.6	36.0	37.5	39.0	40.5	42.1	43.8	45.6	47.4	49.3	51.3	53.3	55.4	57.7	60.0
Diluted shares	0.8	1.1	8.3	22.9	35.2	36.7	38.1	39.6	41.2	42.9	44.6	46.4	48.2	50.2	52.2	54.3	56.4	58.7	61.0	63.5

Source: Cowen and Company

Valuation Methodology & Investment Risks

Valuation Methodology

Biotechnology:

In calculating our 12-month target price, we employ one or more valuation methodologies, which include a discounted earnings analysis, discounted cash flow analysis, net present value analysis and/or a comparable company analysis. These analyses may or may not require the use of objective measures such as price-to-earnings or price-to-sales multiples as well as subjective measures such as discount rates.

We make investment recommendations on early stage (pre-commercial) biotechnology companies based upon an assessment of their technology, the probability of pipeline success, and the potential market opportunity in the event of success. However, because these companies lack traditional financial metrics, we do not believe there are any good methodologies for assigning a specific target price to such stocks.

Investment Risks

Biotechnology:

There are multiple risks that are inherent with an investment in the biotechnology sector. Beyond systemic risk, there is also clinical, regulatory, and commercial risk. Additionally, biotechnology companies require significant amounts of capital in order to develop their clinical programs. The capital-raising environment is always changing and there is risk that necessary capital to complete development may not be readily available.

Company Specific Risks

Risks to our Outperform rating on FATE shares include: 1) delays or clinical setbacks in the development of ProHema, 2) delays or setbacks in the development of the Wnt7a program, 3) the possibility of additional financings, and 4) a change in the appetite for early-stage company risk among healthcare investors.

Addendum

STOCKS MENTIONED IN IMPORTANT DISCLOSURES

Ticker	Company Name
FATE	Fate Therapeutics, Inc.

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

Cowen and Company, LLC and or its affiliates make a market in the stock of Fate Therapeutics, Inc. securities.

Fate Therapeutics, Inc. has been client(s) of Cowen and Company, LLC in the past 12 months.

Cowen and Company, LLC and/or its affiliates expect to receive, or intend to seek, compensation for investment banking services in the next 3 months from Fate Therapeutics, Inc..

Fate Therapeutics, Inc. is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from Fate Therapeutics, Inc..

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of Fate Therapeutics, Inc. within the past twelve months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Price Targets: Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Copyright, User Agreement and other general information related to this report

Cowen and Company, LLC. New York (646) 562-1000 **Boston** (617) 946-3700 **San Francisco** (415) 646-7200 **Chicago** (312) 577-2240 **Cleveland** (440) 331-3531 **Atlanta** (866) 544-7009 **London** (affiliate) 44-207-071-7500

COWEN AND COMPANY RATING DEFINITIONS

Cowen and Company Rating System effective May 25, 2013

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Rating System until May 25, 2013

Outperform (1): Stock expected to outperform the S&P 500

Neutral (2): Stock expected to perform in line with the S&P 500

Underperform (3): Stock expected to underperform the S&P 500

Assumptions: Time horizon is 12 months; S&P 500 is flat over forecast period

Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

Buy – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

Sell – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

Hold – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

COWEN AND COMPANY RATING ALLOCATION

Distribution of Ratings/Investment Banking Services (IB) as of 09/30/13

Rating	Count	Ratings Distribution	Count	IB Services/Past 12 Months
Buy (a)	394	58.72%	54	13.71%
Hold (b)	255	38.00%	5	1.96%
Sell (c)	22	3.28%	1	4.55%

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.



Legend for Price Chart:

I = Initation | 1 = Outperform | 2 = Market Perform | 3 = Underperform | UR = Price Target Under Review | T = Terminated Coverage | $xx = Price Target | NA = Not Available